• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Advances in the treatment of metastatic prostate cancer in China.

作者信息

Wang Baojun, Liu Zhenhua, Yang Luyao, Zhang Xu

机构信息

Department of Urology, Chinese PLA General Hospital, Beijing 100853, China.

Value & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai 200233, China.

出版信息

Cancer Biol Med. 2025 May 19;22(5):433-8. doi: 10.20892/j.issn.2095-3941.2025.0065.

DOI:10.20892/j.issn.2095-3941.2025.0065
PMID:40387589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12240182/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e852/12240182/4b73b7c98eb3/cbm-22-05-433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e852/12240182/4b73b7c98eb3/cbm-22-05-433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e852/12240182/4b73b7c98eb3/cbm-22-05-433-g001.jpg

相似文献

1
Advances in the treatment of metastatic prostate cancer in China.中国转移性前列腺癌的治疗进展
Cancer Biol Med. 2025 May 19;22(5):433-8. doi: 10.20892/j.issn.2095-3941.2025.0065.
2
[Expert consensus on whole-course management of prostate cancer (2025 edition)].《前列腺癌全程管理专家共识（2025版）》
Zhonghua Zhong Liu Za Zhi. 2025 Jul 23;47(7):617-634. doi: 10.3760/cma.j.cn112152-20250212-00053.
3
Recent advances in the molecular targeted drugs for prostate cancer.前列腺癌分子靶向药物的最新进展。
Int Urol Nephrol. 2023 Apr;55(4):777-789. doi: 10.1007/s11255-023-03487-3. Epub 2023 Jan 31.
4
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效：系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
5
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.转移性激素敏感型前列腺癌治疗的临床试验研究能否转化为患者在“真实世界”中获得治疗的机会？一项系统评价。
Eur Urol Oncol. 2024 Feb;7(1):14-24. doi: 10.1016/j.euo.2023.05.002. Epub 2023 Jun 27.
6
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
7
Prostate-Related Germline Variant Frequencies Detected in a Cohort of Men With Metastatic Prostate Cancer in Northern India.在印度北部一组转移性前列腺癌男性患者中检测到的前列腺相关种系变异频率。
JCO Precis Oncol. 2025 Jul;9:e2500130. doi: 10.1200/PO-25-00130. Epub 2025 Jul 10.
8
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.对于开始接受雄激素剥夺治疗的转移性前列腺癌患者使用二甲双胍：STAMPEDE平台方案的一项随机3期试验
Lancet Oncol. 2025 Jul 7. doi: 10.1016/S1470-2045(25)00231-1.
9
Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.多西他赛后卢-PSMA-617巩固治疗同步高负荷转移性激素敏感性前列腺癌患者：一项随机2期试验
J Nucl Med. 2025 Jul 1;66(7):1068-1074. doi: 10.2967/jnumed.125.269913.
10
Immunotherapy in metastatic prostate cancer.转移性前列腺癌的免疫疗法。
Ther Adv Med Oncol. 2025 Jul 3;17:17588359251347857. doi: 10.1177/17588359251347857. eCollection 2025.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.靶向抑制 CYP11A1 在去势抵抗性前列腺癌中的作用。
NEJM Evid. 2024 Jan;3(1):EVIDoa2300171. doi: 10.1056/EVIDoa2300171. Epub 2023 Dec 26.
3
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
尼拉帕利与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌。
J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.
4
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation.迈向循环肿瘤DNA在转移性前列腺癌中的临床应用：整合的机遇与解读的陷阱
Front Oncol. 2022 Nov 10;12:1054497. doi: 10.3389/fonc.2022.1054497. eCollection 2022.
5
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.雷佐利昔胺与比卡鲁胺联合雄激素剥夺疗法治疗高容量转移性激素敏感性前列腺癌患者（CHART）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5.
6
Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis.中国与美国前列腺癌发病率和死亡率的不同趋势：连接点和年龄-时期-队列分析
Front Med (Lausanne). 2022 Feb 3;9:824464. doi: 10.3389/fmed.2022.824464. eCollection 2022.
7
Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.2010年至2020年中国大陆及全球前列腺癌治疗临床试验分析
Front Oncol. 2021 May 12;11:647110. doi: 10.3389/fonc.2021.647110. eCollection 2021.
8
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.镭-223 治疗有症状骨转移去势抵抗性前列腺癌的亚洲患者：一项单臂 3 期研究。
Asia Pac J Clin Oncol. 2021 Dec;17(6):462-470. doi: 10.1111/ajco.13479. Epub 2020 Oct 13.
9
Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.中国前列腺癌患者中综合 DNA 损伤修复基因种系突变的流行率。
Int J Cancer. 2021 Feb 1;148(3):673-681. doi: 10.1002/ijc.33324. Epub 2020 Oct 16.
10
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的生存获益。
N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.